Advanced Treatments: Precision Medicine for MTC

When Medullary Thyroid Carcinoma (MTC) cannot be fully removed by surgery or has spread to other parts of the body (metastasized), the focus shifts to systemic therapy—medications that travel through the entire body.

The primary goal of these systemic therapies is to control the cancer, shrink tumors, and manage symptoms, rather than to provide a permanent cure. We have entered an era of precision oncology, where doctors use “targeted” drugs based on the genetic profile of your tumor.

The Role of Somatic Tumor Testing

While you may have already had a “germline” blood test to see if your cancer is hereditary, your doctor will now perform somatic tumor testing (often using a method called Next-Generation Sequencing or NGS) ^[1].

This test analyzes the DNA of the tumor itself. Even in “sporadic” MTC (non-hereditary), the tumor cells often harbor a RET mutation that was acquired by the cancer as it grew ^[2]. Identifying this specific mutation is the “key” that unlocks the most effective modern treatments ^[3].

Precision Options: Selective vs. Multi-Kinase Inhibitors

Treatment strategies today depend entirely on your tumor’s genetic makeup.

For RET-Mutated Tumors (Selective RET Inhibitors)

If your tumor has a RET mutation, highly selective RET inhibitors like selpercatinib and pralsetinib have become the preferred first-line treatment ^[4][5]. These drugs zero in specifically on the RET protein. Recent clinical trials have shown they offer superior tumor shrinkage and progression-free survival compared to older drugs ^[6].

For RET-Negative / Wildtype Tumors (Multi-Kinase Inhibitors)

It is crucial to understand that selective RET inhibitors only work for tumors with a RET mutation. Up to 40-50% of sporadic MTC cases do not have a somatic RET mutation (they are “RET-wildtype”). For these patients, multi-kinase inhibitors (MKIs) like cabozantinib or vandetanib remain an essential, highly effective standard of care ^[7][8]. These drugs work by blocking multiple different growth signals and blood vessel formation pathways that feed the cancer.

Managing Side Effects and Safety

While modern targeted therapies are incredibly effective, they require careful monitoring:

• Hypertension: High blood pressure is common and often managed with standard BP medications.
• Liver Enzyme Elevation (Hepatotoxicity): Both selpercatinib and pralsetinib can cause liver inflammation, requiring regular blood tests to monitor your liver function.
• QT Prolongation: This is a change in the heart’s electrical rhythm. You will likely need periodic EKGs to ensure your heart is beating safely.
• Pregnancy Precautions: Systemic therapies for MTC carry teratogenic risks (can cause severe birth defects). Patients of childbearing age must discuss family planning and reliable contraception with their care team before starting these medications.

When to Start Treatment

Unlike some other cancers, MTC often grows very slowly. Because these drugs can have side effects and must be taken long-term, doctors typically wait to start systemic therapy until the cancer is causing symptoms or showing clear structural growth on scans ^[9]. Your “calcitonin doubling time”—how fast your blood markers are rising—is often used to help time this decision.